- 7% increase in genomic services provided in Evry in 2024 and stability in activities operated for the Institut Pasteur
- Operating costs cut by 24% and net loss limited to €256k
- Accelerated development of activities for the pharmaceutical industry following CAP accreditation and CLIA certification
Regulatory News:
IntegraGen (FR0010908723 ALINT PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announced its yearly audited annual results 2025, following approval by the Board of Directors on April 10th, 2025.
Bernard Courtieu, Chief Executive Officer of IntegraGen, comments: "On a like-for-like basis, excluding activities linked to the SeqOIA platform with which the five-year contract ended in February, the genomic services activity at the Évry laboratory grew by 7%, while activity on the P2M platform operated for the Institut Pasteur, remained stable. This resumption of growth in genomic services activities, which exceeded €5.5m in revenues, confirms the robustness of our core business.
The 2024 results are, however, heavily impacted by the completion of the 5-year contract with SeqOIA in February 2024; a significant restructuring effort has thus been carried out to massively reduce operating costs, limiting the net loss to €256k.
Thanks to the loyalty of our customers and partners and the exceptional quality of the services provided by all our staff, we are particularly proud to be able to present these results, and more generally to continue our contribution to the projects of researchers and clinicians, ultimately supporting improved patient care. Our commercial efforts towards the pharmaceutical industry are beginning to bear fruit, and several multi-year contracts have already been signed with pharmaceutical and diagnostic laboratories clients, worth more than €3 million."
ACTIVITY
Growth in genomic services activities at the Evry laboratory
Genomic services, which include services provided in support of research and clinical development, are now concentrated at the Évry site. Annual revenue in 2024 for these activities amount to €5,518k, up 7%.
During 2024, IntegraGen expanded of tests offered in accordance with CLIA/CAP standards to include Exome sequencing and also continued the development in residual disease monitoring in oncology use of liquid biopsy.
Stability of services provided for the Institut Pasteur's Shared Microbiology Platform (P2M)
IntegraGen continued to provide services within the Pasteur Institute's P2M platform.
Activity related to Covid-19 continued to decline in 2024, giving way to normal microbiology activity. In 2024, the platform carried out more than 47,000 microbial sequencings.
FINANCIALS
- Income statement
Euro thousands (k€) | 2024 | 2023 | Var.% |
Revenues | 8,698 | 12,537 | -31% |
Other income | 337 | 290 | 16% |
Total Operating income | 9,035 | 12,827 | -30% |
Purchases | -3,255 | -4,211 | -23% |
Labor costs | -3,600 | -4,826 | -25% |
Other external expenses and taxes | -2,931 | -3,709 | -21% |
Gross operating profit | -751 | 81 | n.a. |
Depreciation and provisions | -57 | -198 | -71% |
Total operating expenses | -9,842 | -12,944 | -24% |
Operating result | -807 | -117 | n.a. |
Financial result | 142 | 40 | 258% |
Result of ordinary activities | -665 | -77 | n.a. |
Exceptionnal items | 313 | -181 | -273% |
Taxes (CIR/CII) | 96 | 88 | 10% |
Net result | -256 | -171 | 50% |
Operating income amounted to €9,035,000, down 30% compared to 2023. This decrease is mainly due to the completion of the contract with GCS SeqOIA in February 2024.
On a like-for-like basis, excluding SeqOIA, revenue increased by 5%, driven by growth in the core genomic services business in Evry (+7%).
Operating expenses amounted to €9,842k, also down 24% compared with the previous year. This change is mainly due to lower orders for reagents, linked to the discontinuation of orders for SeqOIA, the optimization of sequencer utilization, a restructuring plan initiated at the end of 2023 and rolled out in the first quarter of 2024, and finally, an overall reduction in external expenses.
As a result of these various developments, the company was able to control costs and, despite a highly inflationary environment, net income for the year came to -€256k, down -€73k compared to 2023 (-€171k).
Balance sheet
Assets
En k | 31/12/2024 | 31/12/2023 |
Non current assets | 250 | 316 |
Inventories | 205 | 311 |
Trade receivables | 1,671 | 2,960 |
Other receivables | 1,485 | 1,535 |
Cash and cash equivalents | 1,900 | 2,879 |
Current assets | 5,262 | 7,684 |
Translation adjustment assets | 4 | |
TOTAL ASSETS | 5,515 | 8,000 |
Liabilities
En k | 31/12/2024 | 31/12/2023 |
Shareholders' equity | 1,755 | 2,011 |
Provisions for liabilities and charges | 12 | 157 |
Financial debt | 643 | 1,125 |
Advances received | ||
Operating liabilities | 1,938 | 2,915 |
Other liabilities | 1,166 | 1,784 |
Exchange conversion | 0 | 9 |
TOTAL LIABILITIES | 5,515 | 8,000 |
The cash position at the end of December 2024 amounted to €1,900k, compared with €2,879k at December 31, 2023, representing a decrease of €979k. This change is mainly due to the repayment of loans (including the state-guaranteed loan obtained in 2020, which will be repaid in full in June 2026) for €400,000, with the balance being attributable to changes in working capital requirements, operating consumption and exceptional items such as the sale of certain assets to the SeqOIA laboratory.
OUTLOOK FOR 2025: CONTINUED GROWTH AND FOCUS ON THE GENOMIC SERVICES BUSINESS AT THE EVRY LABORATORY, WITH PRIORITY GIVEN TO SERVICES TO THE PHARMACEUTICAL INDUSTRY
The company plans to continue growing at a similar pace in 2025, with an increase in the size and profitability of its multi-year projects, enabling it to leverage its sequencing capabilities as well as IntegraGen's expertise in project design, reporting, and the organization of operational workflows for clinical research projects for the pharmaceutical industry. In this regard, the company signed two multi-year projects at the beginning of the year for two laboratories with a total value of more than €3.5 million.
ABOUT INTEGRAGEN
IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and genomic data interpretation software. The company runs one of the largest NGS labs in France and operates for research institutes of excellence. As part of OncoDNA group, IntegraGen leverages the power of next generation sequencing with the mission of delivering the promise of precision medicine to patients. IntegraGen has about 40 employees and generated €9 million of turnover in 2024. Based in France, IntegraGen is part of the Belgian OncoDNA group present in Spain, UK, Germany and works with an international network of 35 distributors. The Group also provides biomarker testing and clinical interpretation tools to guide treatment and monitoring of late stage solid tumors and accelerate the development of new cancer drugs. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 Mnemo: ALINT PEA-PME eligible).
For more information, visit www.integragen.com and follow us on LinkedIn or Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250429061469/en/
Contacts:
IntegraGen
Bernard COURTIEU
CEO
Virginie Decoster
CFO
contact@integragen.com
Tel.: +33 (0)1 60 91 09 00
NewCap
Relations Investisseurs
Louis-Victor DELOUVRIER
integragen@newcap.eu
Tel.: +33 (0)1 44 71 98 53
